Clinical particulars.
Target species
Dogs
Indications for use, specifying the target species
For treatment of clinical signs related to congestive heart failure in dogs, including pulmonary oedema.
Contraindications
Do not use in cases of renal failure. Do not use in cases of dehydration, hypovolaemia or hypotension. Do not use concomitantly with other loop diuretics. Do not use in cases of hypersensitivity to the active substance or to any of the excipients.
Special warnings for each target species
The initial/maintenance dose may be temporarily increased when pulmonary oedema becomes more severe, i.e. reaching alveolar oedema state (see section Amounts to be administered and administration route).
Special precautions for use
Special precautions for use in animals
In dogs presenting with acute pulmonary oedema requiring emergency treatment, the use of injectable medicinal products should be considered first before commencing oral diuretic therapy.
Renal function (measurement of blood urea and creatinine as well as urine protein: creatinine (UPC) ratio), hydration status and serum electrolytes status should be monitored prior to and during treatment at very regular intervals according to the benefit-risk assessment performed by the responsible veterinarian (see Contraindications and Adverse reactions). The diuretic response to torasemide may increase over time upon repeated dosing, particularly at doses greater than 0.2 mg/kg/day; therefore more frequent monitoring should be considered.
Torasemide should be used with caution in cases of diabetes mellitus. Monitoring of glycaemia in diabetic animals is recommended prior to and during treatment. In dogs with pre-existing electrolyte and/or water imbalance, this should be corrected prior to treatment with torasemide.
As torasemide increases thirst, dogs should have free access to fresh water. In case of loss of appetite and/or vomiting and/or lethargy or in case of treatment adjustment, renal function (blood urea and creatinine as well as urine protein:creatinine (UPC) ratio) should be assessed.
In a clinical field trial, the efficacy of Isemid was demonstrated when it was used as a first line treatment. Transferring treatment from an alternative loop diuretic to this veterinary medicinal product has not been evaluated and such a change should only be implemented based on a benefit-risk assessment performed by the responsible veterinarian.
The safety and efficacy of the product has not been assessed for dogs weighing less than 2.5 kg. For these animals use only according to the benefit/risk assessment by the responsible veterinarian.
The tablets are flavoured.
Special precautions to be taken by the person administering the veterinary medicinal product to animals
This veterinary medicinal product may cause increased urination, thirst and/or gastrointestinal disturbances and/or hypotension and/or dehydration if ingested. Any part-used tablets should be returned to the blister pack and then to the original carton to help prevent access by children. In case of accidental ingestion, particularly by a child, seek medical advice immediately and show the package leaflet or the label to the physician.
This veterinary medicinal product may cause hypersensitivity (allergic) reactions in persons that are sensitized to torasemide. People with known hypersensitivity to torasemide, to sulfonamides or to any of the excipients should avoid contact with the veterinary medicinal product. If symptoms of allergy occur, seek medical advice and show the product packaging to the physician.
Wash hands after use.
Adverse reactions (frequency and seriousness)
In a clinical field study, renal insufficiency, an increase in renal blood parameters, haemoconcentration and alterations in electrolyte levels (chloride, sodium, potassium, phosphorus, magnesium, calcium) were very commonly observed.
The following clinical signs were observed commonly: episodic gastrointestinal signs such as vomiting and diarrhoea, dehydration, polyuria, polydipsia, urinary incontinence, anorexia, weight loss and lethargy. Other effects consistent with the pharmacological activity of torasemide were observed in pre-clinical studies in healthy dogs at the recommended dose, i.e. dry mucosa of the oral cavity, reversible increases in glucose and aldosterone serum concentrations, decrease in urine specific gravity and increase in urine pH.
Use during pregnancy, lactation or lay
Laboratory studies in rats and rabbits have shown foetotoxicity at maternotoxic doses. As the safety of the product has not been established in the target species, the use of the product is not recommended during pregnancy, lactation and breeding animals.
Interaction with other medicinal products and other forms of interaction
Co-administration of loop diuretics and NSAIDs can result in a decreased natriuretic response. Concomitant use with NSAIDs, aminoglycosides or cephalosporins may increase the risk of nephrotoxicity and/or ototoxicity of those medicinal products. Torasemide may antagonise the action of oral hypoglycaemic agents. Torasemide may increase the risk of sulfonamide allergy.
In cases of co-administration with corticosteroids, the effects of loss of potassium may be potentiated.
In cases of co-administration with amphotericin B, increased potential for nephrotoxicity and intensification of electrolyte imbalance can be observed.
No pharmacokinetic interactions have been reported following co-administration of torasemide with digoxin; however hypokalaemia can enhance digoxin-induced arrhythmias.
Torasemide can reduce the renal excretion of salicylates, leading to an increased risk of toxicity.
Care should be exercised when administering torasemide with other highly plasma protein bound drugs. Since protein binding facilitates the renal secretion of torasemide, a decrease in binding due to displacement by another drug may be a cause of diuretic resistance. Concomitant administration of torasemide with other substances metabolised by cytochrome P450 families 3A4 (e.g.: enalapril, buprenorphine, doxycycline, cyclosporine) and 2E1 (isoflurane, sevoflurane, theophylline) may decrease their clearance from the systemic circulation. The effect of antihypertensive veterinary medicinal products, especially angiotensin converting enzyme (ACE)-inhibitors, may be potentiated when co-administered with torasemide.
Amounts to be administered and administration route
Oral use. The recommended initial/maintenance dose is 0.13 to 0.25 mg torasemide/kg bodyweight/day, once daily. In case of moderate or severe pulmonary oedema, this dose can be increased if necessary up to a maximum dose of 0.4 mg/kg bodyweight/day once daily. Doses of 0.26 mg/kg and higher should only be administered for a maximum period of 5 days. After this period, the dose should be reduced to the maintenance dose and the dog should be evaluated by the veterinarian in a few days. The following table shows the dose adjustment scheme within the recommended dose range of 0.13 to 0.4 mg/kg/day:
Dog Bodyweight (kg)
Number and strength of Isemid tablets to be administered
Initial/Maintenance dose
(0.13 to 0.25 mg/kg/day)
Temporary high dose
(0.26 to 0.40 mg/kg/day)
1 mg
2.5 to 4
½
1
> 4 to 6
1
1 + ½
> 6 to 8
From 1 to 1 + ½
From 2 to 2 + ½
> 8 to 11.5
From 1+ ½ to 2
From 2 + ½ to 3
2mg
> 11.5 to 15
From 1 to 1 + ½
2
> 15 to 23
From 1 + ½ to 2
From 2 + ½ to 3
4mg
> 23 to 30
From 1 to 1 + ½
2
> 30 to 40
From 1 + ½ to 2
From 2 + ½ to 3
> 40 to 60
From 2 to 2 + ½
From 3 to 4
The dose should be adjusted to maintain patient comfort with attention to renal function and electrolytes status. Once signs of congestive heart failure have been controlled and the patient is stable, it should be continued at the lowest effective dose, if long term diuretic therapy with this product is required. If the tablet is not spontaneously taken by the dog, it can also be given with food or directly into the mouth.
Overdose (symptoms, emergency procedures, antidotes), if necessary
After administration to healthy dogs of 3 times and 5 times the maximum dose for 5 consecutive days followed by 177 daily administrations of 3 times and 5 times the highest therapeutic recommended dose for maintenance, histopathological changes in the kidneys (interstitial inflammation, dilatation of renal tubules and subscapular cysts) were noted in addition to the effects observed after the administration of the recommended dose (see Adverse reactions). The renal lesions were still present at 28 days after the end of treatment. Microscopic characteristics of the lesions suggest an ongoing repair process. These lesions may most likely be considered as a result of the pharmacodynamic effect (diuresis) and were not associated with evidence of glomerulosclerosis or interstitial fibrosis. Transient dose response alterations in the adrenal glands, consisting of minimal to moderate reactive hypertrophy/hyperplasia, presumably related to high production of aldosterone, were observed in the dogs treated with up to 5 times the highest therapeutic recommended dose. An increase in albumin serum concentration was observed. ECG alterations without any clinical signs (increase in P wave and/or QT interval) were observed in some animals after the administration of 5 times the highest recommended dose. The causative role of changes in plasma electrolyte values cannot be excluded.
After administration of 3 and 5 times the highest therapeutic recommended dose to healthy dogs, a decrease of appetite was observed which led to a weight loss in some cases.
In case of overdose, treatment would be at the discretion of the responsible veterinarian, based on the presenting signs.
Withdrawal period(s)
Not applicable.
Pharmacological particulars
Pharmacotherapeutic group: Cardiovascular system, high-ceiling diuretics, plain sulfonamides. ATCvet code: QC03CA04
Pharmacodynamic properties
Torasemide belongs to the pyridine-3-sulfonylurea class of loop diuretics, also called high-ceiling diuretics. Torasemide has a chemical structure between those of loop diuretics (such as furosemide) and Cl- channel blockers. The primary site of action of torasemide is the thick ascending limb of the loop of Henle, where it interacts with the Na+ -K+ -2Cl- cotransporter localised in the luminal membrane (urine side) and blocks the active reabsorption of sodium and chloride. Therefore, diuretic activity of torasemide correlates better with the rate of torasemide excretion in the urine than with the concentration in the blood. Since the ascending limb of the loop of Henle is impermeable to water, the inhibition of Na+ and Cl- movement from the lumen to the interstitial space increases the concentration of ions in the lumen and produces a hypertonic medullary interstitium. Consequently, water reabsorption from the collecting duct is inhibited and the volume of water on the luminal side is increased. Torasemide causes a significant, dose-dependent increase in urine flow and the urinary excretion of sodium and potassium. Torasemide has a more potent, longer-acting diuretic activity than furosemide.
Pharmacokinetic particulars
In dogs, following a single intravenous dose of 0.2 mg torasemide/kg bodyweight, the mean total clearance was 22.1 mL/h/kg, with a mean volume of distribution of 166 mL/kg and a mean terminal half-life of about 6 hours. After oral administration of 0.2 mg torasemide/kg bodyweight, the absolute bioavailability is about 99% based on plasma concentration-time data and 93% based on urine concentration-time data. Feeding significantly increased torasemide AUC0-8 by 37% and slightly delayed Tmax, but in fasted and fed conditions the maximal concentrations (Cmax) are approximately the same (2015 µg/L vs 2221 µg/L, respectively). Furthermore, the diuretic effect of torasemide is approximately the same in fed and fasted conditions. Consequently, the medicinal product can be administered with or without food.
In dogs, the plasma protein binding is > 98%. A large proportion of the dose (about 60%) is excreted in the urine as unchanged parent substance. The proportion of torasemide excreted in the urine is approximately the same in fasted or fed conditions (61% vs. 59% respectively). Two metabolites (a dealkylated and a hydroxylated metabolite) have been identified in urine. The parent substance is metabolised by the hepatic cytochrome P450 families 3A4 and 2E1, and to a lesser extent by 2C9. No accumulation of torasemide is observed after repeated once daily oral administration for 10 days, whatever the dose administered (ranging from 0.1 to 0.4 mg/kg) even if a slight supra dose proportionality is observed.
Pharmaceutical particulars
List of excipients
Lactose monohydrate , Cellulose microcrystalline, Povidone (K30), Pork liver powder flavour, Compressible sugar, Crospovidone (type B), Magnesium stearate.
Major incompatibilities
Not applicable.
Shelf life
Shelf life of the veterinary medicinal product as packaged for sale: 4 years.
Special precautions for storage
This veterinary medicinal product does not require any special storage conditions.
Remaining tablet parts should be stored in the blister and be given at the next administration.
Keep the tablets out of the reach of animals in order to avoid any accidental ingestion.
Nature and composition of immediate packaging
Blister pack of polyamide/aluminium/PVC, thermo-sealed by an aluminium foil (each blister contains 10 tablets) and packaged in a cardboard box.
All strengths are available in the following pack sizes: Pack sizes of 30 or 90 tablets.
Not all pack sizes may be marketed.
Special precautions for the disposal of unused veterinary medicinal product or waste materials derived from the use of such products
Any unused veterinary medicinal product or waste materials derived from such veterinary medicinal product should be disposed of in accordance with local requirements.
Target species
Dogs
Indications for use, specifying the target species
For treatment of clinical signs related to congestive heart failure in dogs, including pulmonary oedema.
Contraindications
Do not use in cases of renal failure. Do not use in cases of dehydration, hypovolaemia or hypotension. Do not use concomitantly with other loop diuretics. Do not use in cases of hypersensitivity to the active substance or to any of the excipients.
Special warnings for each target species
The initial/maintenance dose may be temporarily increased when pulmonary oedema becomes more severe, i.e. reaching alveolar oedema state (see section Amounts to be administered and administration route).
Special precautions for use
Special precautions for use in animals
In dogs presenting with acute pulmonary oedema requiring emergency treatment, the use of injectable medicinal products should be considered first before commencing oral diuretic therapy.
Renal function (measurement of blood urea and creatinine as well as urine protein: creatinine (UPC) ratio), hydration status and serum electrolytes status should be monitored prior to and during treatment at very regular intervals according to the benefit-risk assessment performed by the responsible veterinarian (see Contraindications and Adverse reactions). The diuretic response to torasemide may increase over time upon repeated dosing, particularly at doses greater than 0.2 mg/kg/day; therefore more frequent monitoring should be considered.
Torasemide should be used with caution in cases of diabetes mellitus. Monitoring of glycaemia in diabetic animals is recommended prior to and during treatment. In dogs with pre-existing electrolyte and/or water imbalance, this should be corrected prior to treatment with torasemide.
As torasemide increases thirst, dogs should have free access to fresh water. In case of loss of appetite and/or vomiting and/or lethargy or in case of treatment adjustment, renal function (blood urea and creatinine as well as urine protein:creatinine (UPC) ratio) should be assessed.
In a clinical field trial, the efficacy of Isemid was demonstrated when it was used as a first line treatment. Transferring treatment from an alternative loop diuretic to this veterinary medicinal product has not been evaluated and such a change should only be implemented based on a benefit-risk assessment performed by the responsible veterinarian.
The safety and efficacy of the product has not been assessed for dogs weighing less than 2.5 kg. For these animals use only according to the benefit/risk assessment by the responsible veterinarian.
The tablets are flavoured.
Special precautions to be taken by the person administering the veterinary medicinal product to animals
This veterinary medicinal product may cause increased urination, thirst and/or gastrointestinal disturbances and/or hypotension and/or dehydration if ingested. Any part-used tablets should be returned to the blister pack and then to the original carton to help prevent access by children. In case of accidental ingestion, particularly by a child, seek medical advice immediately and show the package leaflet or the label to the physician.
This veterinary medicinal product may cause hypersensitivity (allergic) reactions in persons that are sensitized to torasemide. People with known hypersensitivity to torasemide, to sulfonamides or to any of the excipients should avoid contact with the veterinary medicinal product. If symptoms of allergy occur, seek medical advice and show the product packaging to the physician.
Wash hands after use.
Adverse reactions (frequency and seriousness)
In a clinical field study, renal insufficiency, an increase in renal blood parameters, haemoconcentration and alterations in electrolyte levels (chloride, sodium, potassium, phosphorus, magnesium, calcium) were very commonly observed.
The following clinical signs were observed commonly: episodic gastrointestinal signs such as vomiting and diarrhoea, dehydration, polyuria, polydipsia, urinary incontinence, anorexia, weight loss and lethargy. Other effects consistent with the pharmacological activity of torasemide were observed in pre-clinical studies in healthy dogs at the recommended dose, i.e. dry mucosa of the oral cavity, reversible increases in glucose and aldosterone serum concentrations, decrease in urine specific gravity and increase in urine pH.
Use during pregnancy, lactation or lay
Laboratory studies in rats and rabbits have shown foetotoxicity at maternotoxic doses. As the safety of the product has not been established in the target species, the use of the product is not recommended during pregnancy, lactation and breeding animals.
Interaction with other medicinal products and other forms of interaction
Co-administration of loop diuretics and NSAIDs can result in a decreased natriuretic response. Concomitant use with NSAIDs, aminoglycosides or cephalosporins may increase the risk of nephrotoxicity and/or ototoxicity of those medicinal products. Torasemide may antagonise the action of oral hypoglycaemic agents. Torasemide may increase the risk of sulfonamide allergy.
In cases of co-administration with corticosteroids, the effects of loss of potassium may be potentiated.
In cases of co-administration with amphotericin B, increased potential for nephrotoxicity and intensification of electrolyte imbalance can be observed.
No pharmacokinetic interactions have been reported following co-administration of torasemide with digoxin; however hypokalaemia can enhance digoxin-induced arrhythmias.
Torasemide can reduce the renal excretion of salicylates, leading to an increased risk of toxicity.
Care should be exercised when administering torasemide with other highly plasma protein bound drugs. Since protein binding facilitates the renal secretion of torasemide, a decrease in binding due to displacement by another drug may be a cause of diuretic resistance. Concomitant administration of torasemide with other substances metabolised by cytochrome P450 families 3A4 (e.g.: enalapril, buprenorphine, doxycycline, cyclosporine) and 2E1 (isoflurane, sevoflurane, theophylline) may decrease their clearance from the systemic circulation. The effect of antihypertensive veterinary medicinal products, especially angiotensin converting enzyme (ACE)-inhibitors, may be potentiated when co-administered with torasemide.
Amounts to be administered and administration route
Oral use. The recommended initial/maintenance dose is 0.13 to 0.25 mg torasemide/kg bodyweight/day, once daily. In case of moderate or severe pulmonary oedema, this dose can be increased if necessary up to a maximum dose of 0.4 mg/kg bodyweight/day once daily. Doses of 0.26 mg/kg and higher should only be administered for a maximum period of 5 days. After this period, the dose should be reduced to the maintenance dose and the dog should be evaluated by the veterinarian in a few days. The following table shows the dose adjustment scheme within the recommended dose range of 0.13 to 0.4 mg/kg/day:
Dog Bodyweight (kg)
Number and strength of Isemid tablets to be administered
Initial/Maintenance dose
(0.13 to 0.25 mg/kg/day)
Temporary high dose
(0.26 to 0.40 mg/kg/day)
1 mg
2.5 to 4
½
1
> 4 to 6
1
1 + ½
> 6 to 8
From 1 to 1 + ½
From 2 to 2 + ½
> 8 to 11.5
From 1+ ½ to 2
From 2 + ½ to 3
2mg
> 11.5 to 15
From 1 to 1 + ½
2
> 15 to 23
From 1 + ½ to 2
From 2 + ½ to 3
4mg
> 23 to 30
From 1 to 1 + ½
2
> 30 to 40
From 1 + ½ to 2
From 2 + ½ to 3
> 40 to 60
From 2 to 2 + ½
From 3 to 4
The dose should be adjusted to maintain patient comfort with attention to renal function and electrolytes status. Once signs of congestive heart failure have been controlled and the patient is stable, it should be continued at the lowest effective dose, if long term diuretic therapy with this product is required. If the tablet is not spontaneously taken by the dog, it can also be given with food or directly into the mouth.
Overdose (symptoms, emergency procedures, antidotes), if necessary
After administration to healthy dogs of 3 times and 5 times the maximum dose for 5 consecutive days followed by 177 daily administrations of 3 times and 5 times the highest therapeutic recommended dose for maintenance, histopathological changes in the kidneys (interstitial inflammation, dilatation of renal tubules and subscapular cysts) were noted in addition to the effects observed after the administration of the recommended dose (see Adverse reactions). The renal lesions were still present at 28 days after the end of treatment. Microscopic characteristics of the lesions suggest an ongoing repair process. These lesions may most likely be considered as a result of the pharmacodynamic effect (diuresis) and were not associated with evidence of glomerulosclerosis or interstitial fibrosis. Transient dose response alterations in the adrenal glands, consisting of minimal to moderate reactive hypertrophy/hyperplasia, presumably related to high production of aldosterone, were observed in the dogs treated with up to 5 times the highest therapeutic recommended dose. An increase in albumin serum concentration was observed. ECG alterations without any clinical signs (increase in P wave and/or QT interval) were observed in some animals after the administration of 5 times the highest recommended dose. The causative role of changes in plasma electrolyte values cannot be excluded.
After administration of 3 and 5 times the highest therapeutic recommended dose to healthy dogs, a decrease of appetite was observed which led to a weight loss in some cases.
In case of overdose, treatment would be at the discretion of the responsible veterinarian, based on the presenting signs.
Withdrawal period(s)
Not applicable.
Pharmacological particulars
Pharmacotherapeutic group: Cardiovascular system, high-ceiling diuretics, plain sulfonamides. ATCvet code: QC03CA04
Pharmacodynamic properties
Torasemide belongs to the pyridine-3-sulfonylurea class of loop diuretics, also called high-ceiling diuretics. Torasemide has a chemical structure between those of loop diuretics (such as furosemide) and Cl- channel blockers. The primary site of action of torasemide is the thick ascending limb of the loop of Henle, where it interacts with the Na+ -K+ -2Cl- cotransporter localised in the luminal membrane (urine side) and blocks the active reabsorption of sodium and chloride. Therefore, diuretic activity of torasemide correlates better with the rate of torasemide excretion in the urine than with the concentration in the blood. Since the ascending limb of the loop of Henle is impermeable to water, the inhibition of Na+ and Cl- movement from the lumen to the interstitial space increases the concentration of ions in the lumen and produces a hypertonic medullary interstitium. Consequently, water reabsorption from the collecting duct is inhibited and the volume of water on the luminal side is increased. Torasemide causes a significant, dose-dependent increase in urine flow and the urinary excretion of sodium and potassium. Torasemide has a more potent, longer-acting diuretic activity than furosemide.
Pharmacokinetic particulars
In dogs, following a single intravenous dose of 0.2 mg torasemide/kg bodyweight, the mean total clearance was 22.1 mL/h/kg, with a mean volume of distribution of 166 mL/kg and a mean terminal half-life of about 6 hours. After oral administration of 0.2 mg torasemide/kg bodyweight, the absolute bioavailability is about 99% based on plasma concentration-time data and 93% based on urine concentration-time data. Feeding significantly increased torasemide AUC0-8 by 37% and slightly delayed Tmax, but in fasted and fed conditions the maximal concentrations (Cmax) are approximately the same (2015 µg/L vs 2221 µg/L, respectively). Furthermore, the diuretic effect of torasemide is approximately the same in fed and fasted conditions. Consequently, the medicinal product can be administered with or without food.
In dogs, the plasma protein binding is > 98%. A large proportion of the dose (about 60%) is excreted in the urine as unchanged parent substance. The proportion of torasemide excreted in the urine is approximately the same in fasted or fed conditions (61% vs. 59% respectively). Two metabolites (a dealkylated and a hydroxylated metabolite) have been identified in urine. The parent substance is metabolised by the hepatic cytochrome P450 families 3A4 and 2E1, and to a lesser extent by 2C9. No accumulation of torasemide is observed after repeated once daily oral administration for 10 days, whatever the dose administered (ranging from 0.1 to 0.4 mg/kg) even if a slight supra dose proportionality is observed.
Pharmaceutical particulars
List of excipients
Lactose monohydrate , Cellulose microcrystalline, Povidone (K30), Pork liver powder flavour, Compressible sugar, Crospovidone (type B), Magnesium stearate.
Major incompatibilities
Not applicable.
Shelf life
Shelf life of the veterinary medicinal product as packaged for sale: 4 years.
Special precautions for storage
This veterinary medicinal product does not require any special storage conditions.
Remaining tablet parts should be stored in the blister and be given at the next administration.
Keep the tablets out of the reach of animals in order to avoid any accidental ingestion.
Nature and composition of immediate packaging
Blister pack of polyamide/aluminium/PVC, thermo-sealed by an aluminium foil (each blister contains 10 tablets) and packaged in a cardboard box.
All strengths are available in the following pack sizes: Pack sizes of 30 or 90 tablets.
Not all pack sizes may be marketed.
Special precautions for the disposal of unused veterinary medicinal product or waste materials derived from the use of such products
Any unused veterinary medicinal product or waste materials derived from such veterinary medicinal product should be disposed of in accordance with local requirements.
Shipping charges mainland GB zone1
| Value | Weight | Delivery Charge |
| Over £49.00 | Any Weight | FREE |
| Under £49.00 | No weight limit | £4.50 |
| Under £49.00 | Under 250 grams | £3.49 |
Most orders are despatched the same day and standard delivery is 3 to 5 working days from despatch. FAST Expedited options are available at extra cost - these usually arrive in 24-48hrs from dispatch but delays are possible during busy periods.
Postcodes outside of Zone 1 (including some areas within mainland UK) may incur extra carriage charges due to surcharges imposed by the couriers. These will be calculated on the website at the checkout.
NB: Orders placed with faster delivery must be placed before 13:00 to ensure same day dispatch (excluding weekends and bank holidays). Please also check on the product page that the items ordered show 'In Stock' otherwise your order will be delayed until the stock becomes available, which in most cases will only be 24hrs.
Estimated "Usually shipped in" information is shown against most products
Overseas orders
We no longer send goods outside of the UK.
Prescription Items
Prescription items will be sent on receipt of a legally valid signed and dated prescription.
Pick up
We offer a pickup service for orders placed over the phone.
Please ring us on 01833 641112 for more information.
Refrigerated Items
- Refrigerated lines Packaging Cost: Despatched with Woolcool Refrigerated Packaging for £7.50.
Wool cool keeps pharmaceutical products at fridge-like, ambient, or even freezing temperatures for up to 72 hours, and possibly longer depending on the contents and use of ice packs.
Important Delivery Information:
- Receipt Required: Someone must be available to receive the delivery. Woolcool packaging is designed for temperature-controlled goods, so parcels cannot be left unattended.
- Immediate Refrigeration: Upon receipt, refrigerate the contents immediately to ensure your food or medicine remains at the correct temperature.
- Failed Delivery Attempts: We are not responsible for the cost of replacements if a delivery attempt fails due to the absence of someone to receive it.
We want you to be completely satisfied with any purchase. If not any item* can be returned to us within 14 days of receipt for exchange or refund Please give us a ring for a returns number on 01833 641112 or alternatively email sales@hyperdrug.co.uk to obtain a returns number.
*Due to legal requirements medicines may not be returned except to correct an error in despatch or in response to an "official recall". If an item is believed to be faulty it should be returned for inspection and it may be necessary to forward it to the manufacturers for testing before replacements or refunds can be authorised. This does not infringe legal rights. Please contact our customer services for a "Returns Number" which must appear on the outside of the package or it will not be accepted. We advise customers to use an insured method of shipping and to retain proof of despatch. We may refuse returns on products specially obtained or manufactured to order. Items must be returned unsoiled and unused and sent adequately packed and carriage paid.
